Michael Nagel

Michael Nagel is an experienced executive in the medical device industry, with a proven track record in sales and marketing. Michael is currently serving as an independent director at Kiromic Biopharma.

Nagel began their career in the medical device industry with Incisive Surgical, where they served as Vice President of Sales and Marketing. During their three-year tenure with the company, Nagel drove sales from $300,000 to $7M. Incisive was acquired by Cooper Surgical during Nagel's time with the company.

Nagel's next role was with Neomend, where they served as Chief Commercial Officer. At Neomend, Nagel was responsible for the initial marketing launch of the company's product, ProGEL. Under Nagel's leadership, sales grew from $0 to $28M in three years. Neomend was eventually sold to C. R. Bard.

Most recently, Nagel has been serving as an independent director at Kiromic Biopharma. In this role, Nagel is responsible for providing strategic guidance and oversight to the company.

Michael Nagel received their MBA from the University of St. Thomas - Opus College of Business in the field of New Ventures. Michael also holds a BA from the University of St. Thomas in the field of Business.